In reclutamento
Cancro gastroesofageo+6
In reclutamentoFarmaco autorizzatoSenza placebo
Studio di fase 2 su Rinatabart Sesutecan e glatiramer acetate in pazienti con tumori gastrointestinali avanzati
Farmaco autorizzatoSenza placebo
- Malattia:Cancro gastroesofageoCancro dello stomaco+5
- Principi attivi:Glatiramer AcetateHUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
Paesi:
Francia
Francia- Partecipanti:18–64 anni · 65 anni e più
- Principi attivi:Glatiramer Acetate